July 2018, Volume 4, Issue 8

July 2018

Volume 4, Issue 8

This issue features a look at attaining gender equality in medicine, refining patient-doctor communication, dealing with clinical trials–induced burnout, and more.

Table of Contents

July 2018 Issue

The Who, What, and When of Managing Adverse Events

Friday, June 29th, 2018
In this edition, Dwight C. Macero, MS, PA-C, discusses the role that advanced practice providers play in managing the side effects of hematologic treatments. Therapies...

Burnout? What Burnout?

Friday, June 29th, 2018
Much has been written in ASH Clinical News about the Orwellian nature of modern clinical trials, and for good reason: Almost all our readers...

July 2018 Issue

A Call to Action on Hematology and Aging, ASH Clinical News Wins Award of...

Friday, June 29th, 2018
A Call to Action on Hematology and Aging The Journal of Geriatric Oncology has published a report by lead author Ashley E. Rosko, MD, from...

Vijay Sankaran Receives Weill Cornell’s Children’s Health Research Award, Scripps Researchers Receive Nearly $3...

Friday, June 29th, 2018
Remembering Frank “Len” Johnson (1945 - 2017)  Frank Leonard “Len” Johnson, MD, a pediatric hematologist/oncologist, passed away on December 24, 2017, after a brief illness. Growing...

July 2018 Issue

Pulling Back the Curtain: Allison Rosenthal, DO

Friday, June 29th, 2018
In this edition, Allison Rosenthal, DO, recounts her experience as a leukemia patient during young adulthood, which destined her for a career in malignant...

Leveling the Playing Field: Can We Achieve Gender Equality in Medicine?

Friday, June 29th, 2018
When Stephanie Abbuhl, MD, professor of emergency medicine at the University of Pennsylvania Perelman School of Medicine, was growing up in the early 1960s,...

July 2018 Issue

How I Treat In Brief: Managing Monoclonal Gammopathy of Undetermined Significance

Friday, June 29th, 2018
This month, Ronald S. Go, MD, and S. Vincent Rajkumar, MD, discuss the management of patients with monoclonal gammopathy of undetermined significance (MGUS). This material was...

How would you reduce the transfusion burden in a patient with CCUS?

Friday, June 29th, 2018
This month, David Steensma, MD, discusses transfusion burden in a patient with clonal cytopenias of undetermined significance. And don't forget to check out next month's...

How would you reduce the transfusion burden in a patient with CCUS?

Friday, June 29th, 2018
Here’s how readers responded to a You Make the Call question about reducing the transfusion burden in a patient with clonal cytopenias of undetermined...

Refining Patient-Doctor Communication

Friday, June 29th, 2018
Refining the patient-doctor relationship became a focus early on in my career. Unlike many of my colleagues in academic hematology and oncology, I also...

July 2018 Issue

Combination Ibrutinib, Carfilzomib, and Dexamethasone Is Promising for Relapsed/Refractory MM

Friday, June 29th, 2018
In a phase I dose-finding study, two-thirds of patients with relapsed/refractory multiple myeloma (MM) responded to the triplet combination of ibrutinib plus carfilzomib and...

Lower Risk of GVHD With Parous Female Sibling Donors Than With Male Unrelated Donors

Friday, June 29th, 2018
Donor’s sex and number of previous pregnancies are well established risk factors for graft-versus-host disease (GVHD) in hematopoietic cell transplantation (HCT), with male sibling...

Could Cord Blood Transplantation Cure Refractory Severe Aplastic Anemia?

Friday, June 29th, 2018
In children and young adults with refractory severe aplastic anemia (SAA) without matched, unrelated donors, cord blood transplantation was associated with low rates of...

Are Strict Eligibility Criteria Keeping Patients From Clinical Trial Participation?

Friday, June 29th, 2018
Eligibility criteria for clinical trials of leukemia therapies may be overly restrictive, limiting trial results’ applicability to real-world clinical practice and leading to unbalanced...

FDA Expands Daratumumab’s Indication to Frontline Myeloma Treatment

Friday, June 29th, 2018
The U.S. Food and Drug Administration (FDA) approved a new indication for the anti-CD38 monoclonal antibody daratumumab, to include the treatment of patients who...

First Biosimilar for Anemia Treatment Approved by FDA

Friday, June 29th, 2018
Epoetin alfa-epbx, a biosimilar to epoetin alfa, was approved for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine...

Trump Administration Reveals Plans to Lower Drug Prices

Friday, June 29th, 2018
In May, President Donald Trump and members of his administration outlined plans to lower prescription drug prices: First, the president unveiled initiatives to remove...

FDA Cracks Down on Unapproved Stem-Cell Clinics

Friday, June 29th, 2018
The U.S. Food and Drug Administration (FDA) filed complaints in May seeking permanent injunctions against two stem cell clinics, U.S. Stem Cell Clinic of...

Andexanet Becomes First FDA-Approved Antidote for Factor Xa Inhibitors

Friday, June 29th, 2018
The U.S. Food and Drug Administration (FDA) granted approval to andexanet alfa, also known as coagulation factor Xa (recombinant), inactivated-zhzo, for the reversal of...

CAR T-Cell Therapy Gets New Indication and New Price

Friday, June 29th, 2018
The U.S. Food and Drug Administration (FDA) has expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to include the treatment...

CVS Unveils Tool to Help Identify Cheaper Treatment Options

Friday, June 29th, 2018
CVS Health introduced the Rx Savings Finder: A system that can check for less expensive medications, higher quantities at lower costs, and drug discounts...

FDA Issues Guidance on Next-Generation Sequencing

Friday, June 29th, 2018
The U.S. Food and Drug Administration (FDA) finalized two guidance documents on recommendations for designing, developing, and validating tests that use next-generation sequencing (NGS)...

NIH Program Completes Genomic Analysis of 33 Cancer Types

Friday, June 29th, 2018
Researchers announced the completion of the PanCancer Atlas, a National Institutes of Health (NIH)–funded, detailed genomic analysis of molecular and clinical information collected from...

Individual Testing Effective, But Costly, in Screening for Zika Virus in Blood Donations

Friday, June 29th, 2018
In March 2016, approximately one year after Zika virus (ZIKV) infections were reported in the United States, the U.S. Food and Drug Administration (FDA)...

July 2018 Issue

Chemotherapy-Free Combination Shows Efficacy in Untreated Follicular Lymphoma

Friday, June 29th, 2018
The randomized, global, phase III RELEVANCE trial showed that a regimen of lenalidomide and rituximab (R2) had similar safety and efficacy to a rituximab-based...

Positive Results With Ivosidenib in Patients With High-Risk, Previously Treated AML

Friday, June 29th, 2018
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec...

Manipulating Natural Killer Cells to Fight Myeloma

Friday, June 29th, 2018
Using cord blood–derived natural killer (NK) cells in hematopoietic cell transplantation (HCT) appears to enhance the effectiveness of the transplant in patients with myeloma,...

Nelarabine and Standard Chemotherapy Improves Disease-Free Survival in Pediatric T-Cell Malignancies

Friday, June 29th, 2018
Adding nelarabine to a standard chemotherapy regimen improved disease-free survival (DFS) in children and young adults with T-cell acute lymphocytic leukemia (TALL), compared with...

Results from ARROW Trial Point to Once-Weekly Carfilzomib Dosing

Friday, June 29th, 2018
Carfilzomib is approved on a twice-weekly dosing schedule for the treatment of relapsed or refractory multiple myeloma (MM), but in the phase III ARROW...

High Rates of Response, Survival With Ibrutinib Plus Rituximab in Waldenström Macroglobulinemia

Friday, June 29th, 2018
Treatment with a combination of ibrutinib and rituximab improved progression-free survival (PFS) over rituximab alone in patients with Waldenström macroglobulinemia (WM), according to results...

SHARE